Ogrič M - Search Results

1

Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA.

Ogrič M, Žigon P, Lakota K, Praprotnik S, Drobne D, Štabuc B, Sodin-Semrl S, Čučnik S. Ogrič M, et al. Clin Rheumatol. 2019 Feb;38(2):361-370. doi: 10.1007/s10067-018-4213-0. Epub 2018 Jul 16. Clin Rheumatol. 2019. PMID: 30014359

2

Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.

Ogrič M, Terčelj M, Praprotnik S, Tomšič M, Božič B, Sodin-Semrl S, Čučnik S. Ogrič M, et al. Immunol Res. 2017 Feb;65(1):172-185. doi: 10.1007/s12026-016-8824-8. Immunol Res. 2017. PMID: 27421721 Review.

3

Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated by Serum Amyloid A.

Lakota K, Hrušovar D, Ogrič M, Mrak-Poljšak K, Čučnik S, Tomšič M, Božič B, Žigon P, Sodin-Semrl S. Lakota K, et al. Among authors: ogric m. Mediators Inflamm. 2018 Feb 13;2018:8237209. doi: 10.1155/2018/8237209. eCollection 2018. Mediators Inflamm. 2018. PMID: 29670468 Free PMC article.

4

Insight into inflammatory cell and cytokine profiles in adult IgA vasculitis.

Kuret T, Lakota K, Žigon P, Ogrič M, Sodin-Šemrl S, Čučnik S, Tomšič M, Hočevar A. Kuret T, et al. Among authors: ogric m. Clin Rheumatol. 2019 Feb;38(2):331-338. doi: 10.1007/s10067-018-4234-8. Epub 2018 Aug 2. Clin Rheumatol. 2019. PMID: 30073458

5

Autoantibodies against dsDNA measured with nonradioactive Farr assay-an alternative for routine laboratories.

Lakota K, Švec T, Kveder T, Sodin-Šemrl S, Žigon P, Ambrožič A, Ogrič M, Markez S, Božič B, Tomšič M, Čučnik S. Lakota K, et al. Among authors: ogric m. Clin Rheumatol. 2019 Feb;38(2):353-359. doi: 10.1007/s10067-018-4271-3. Epub 2018 Sep 10. Clin Rheumatol. 2019. PMID: 30203316

6

Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.

Ogrič M, Žigon P, Drobne D, Štabuc B, Sodin-Semrl S, Čučnik S, Praprotnik S. Ogrič M, et al. Immunol Res. 2018 Dec;66(6):726-736. doi: 10.1007/s12026-018-9050-3. Immunol Res. 2018. PMID: 30569379

7

Neutralizing effects of anti-infliximab antibodies on synergistically-stimulated human coronary artery endothelial cells.

Ogrič M, Poljšak KM, Lakota K, Žigon P, Praprotnik S, Semrl SS, Čučnik S. Ogrič M, et al. Atherosclerosis. 2019 Dec;291:1-8. doi: 10.1016/j.atherosclerosis.2019.09.010. Epub 2019 Sep 20. Atherosclerosis. 2019. PMID: 31629987

8

Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.

Ogrič M, Žigon P, Podovšovnik E, Lakota K, Sodin-Semrl S, Rotar Ž, Čučnik S. Ogrič M, et al. Front Immunol. 2022 May 27;13:876533. doi: 10.3389/fimmu.2022.876533. eCollection 2022. Front Immunol. 2022. PMID: 35711413 Free PMC article.

9

Longitudinal Analysis of Antiphospholipid Antibody Dynamics after Infection with SARS-CoV-2 or Vaccination with BNT162b2.

Ogrič M, Žigon P, Sodin-Semrl S, Zlatković-Švenda M, Zdravković M, Ovuka M, Švec T, Lakota K, Radšel P, Rotar Ž, Čučnik S. Ogrič M, et al. Int J Mol Sci. 2022 Dec 22;24(1):211. doi: 10.3390/ijms24010211. Int J Mol Sci. 2022. PMID: 36613655 Free PMC article.

10

Verification, implementation and harmonization of automated chemiluminescent immunoassays for MPO- and PR3-ANCA detection.

Ogrič M, Švec T, Poljšak KM, Žigon P, Hočevar A, Čučnik S. Ogrič M, et al. Clin Chem Lab Med. 2023 Oct 24;62(4):682-689. doi: 10.1515/cclm-2023-0764. Print 2024 Mar 25. Clin Chem Lab Med. 2023. PMID: 37870064 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters